|IGI Laboratories, Inc.|
105 Lincoln Avenue
United States - Map
IGI Laboratories, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets topical formulations in the United States. It sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms under IGI label. The company also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter (OTC) and cosmetic markets. Its products are used in various applications from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, the company offers pharmaceutical contract services comprising formulating, testing, and/or manufacturing prescription drugs and medical devices; and contract development services consisting of developing topical formulations. It has a license agreement with Novavax, Inc. to utilize the Novasome lipid vesicle encapsulation and certain other technologies for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological OTC and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals. The company was formerly known as IGI, Inc. and changed its name to IGI Laboratories, Inc. in May 2008. IGI Laboratories, Inc. was founded in 1977 and is based in Buena, New Jersey.
|IGI Laboratories, Inc.’s ISS Governance QuickScore as of Oct 1, 2015 is 5. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 3; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Jason Grenfell-Gardner ,
Chief Exec. Officer, Pres and Director
|Mrs. Jenniffer L. Collins ,
Chief Financial Officer and Sec.
|Mr. Sanjay Samudre ,
Director of Operations
|Mr. Stephen Richardson ,
Chief Scientific Officer
|Mr. Thomas Vandervort ,
VP of Bus. Devel.
|Ms. Nadya Lawrence ,
Sr. Vice-Pres of Contract Services
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|